Lim Kenji Rowel Q, Nguyen Quynh, Yokota Toshifumi
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G2H7, Canada.
The Friends of Garrett Cumming Research & Muscular Dystrophy Canada, HM Toupin Neurological Science Research Chair, Edmonton, AB T6G2H7, Canada.
J Pers Med. 2020 Nov 23;10(4):241. doi: 10.3390/jpm10040241.
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder generally caused by out-of-frame mutations in the gene. In contrast, in-frame mutations usually give rise to the milder Becker muscular dystrophy (BMD). However, this reading frame rule does not always hold true. Therefore, an understanding of the relationships between genotype and phenotype is important for informing diagnosis and disease management, as well as the development of genetic therapies. Here, we evaluated genotype-phenotype correlations in DMD and BMD patients enrolled in the Canadian Neuromuscular Disease Registry from 2012 to 2019. Data from 342 DMD and 60 BMD patients with genetic test results were analyzed. The majority of patients had deletions (71%), followed by small mutations (17%) and duplications (10%); 2% had negative results. Two deletion hotspots were identified, exons 3-20 and exons 45-55, harboring 86% of deletions. Exceptions to the reading frame rule were found in 13% of patients with deletions. Surprisingly, C-terminal domain mutations were associated with decreased wheelchair use and increased forced vital capacity. Dp116 and Dp71 mutations were also linked with decreased wheelchair use, while Dp140 mutations significantly predicted cardiomyopathy. Finally, we found that 12.3% and 7% of DMD patients in the registry could be treated with FDA-approved exon 51- and 53-skipping therapies, respectively.
杜氏肌营养不良症(DMD)是一种致命的神经肌肉疾病,通常由该基因的移码突变引起。相比之下,框内突变通常会导致症状较轻的贝克肌营养不良症(BMD)。然而,这种读码框规则并不总是成立。因此,了解基因型与表型之间的关系对于指导诊断和疾病管理以及基因治疗的发展非常重要。在这里,我们评估了2012年至2019年纳入加拿大神经肌肉疾病登记处的DMD和BMD患者的基因型-表型相关性。分析了342例DMD患者和60例BMD患者的基因检测结果数据。大多数患者存在缺失(71%),其次是小突变(17%)和重复(10%);2%检测结果为阴性。确定了两个缺失热点区域,外显子3 - 20和外显子45 - 55,包含86%的缺失。在13%的缺失患者中发现了读码框规则的例外情况。令人惊讶的是,C末端结构域突变与轮椅使用减少和用力肺活量增加有关。Dp116和Dp71突变也与轮椅使用减少有关,而Dp140突变显著预示着心肌病。最后,我们发现登记处中12.3%和7%的DMD患者分别可以接受美国食品药品监督管理局(FDA)批准的外显子51跳跃疗法和外显子53跳跃疗法治疗。